Overview
SILO market data
Price History
SILO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.50 Diluted earnings per share over the trailing twelve months.
- Beta
- -33.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.31 – $15.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.4 · P/B 0.72 · P/S 74.68.
Company News
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug ProgramGlobenewswire Inc · Jul 21, 2026, 1:15 PM
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD PartnershipBenzinga · Jul 14, 2026, 3:45 PM
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent PlatformGlobenewswire Inc · Jul 14, 2026, 1:15 PM
Silo Pharma's QwikAgents Accepted Into Advanced Micro Devices' AMD AI Developer ProgramBenzinga · Jul 14, 2026, 12:56 PM
8-K filing — Silo Pharma, Inc. (SILO)SEC EDGAR · Jul 10, 2026, 10:29 PM
Silo Pharma Announced A Stock And Warrant Offering Involving 619,965 Shares, Priced A Private Placement At $6.452 Per Share With Warrants Exercisable Immediately At $6.21 Per ShareBenzinga · Jul 10, 2026, 12:10 PM
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia InitiativesBenzinga · Jul 7, 2026, 6:25 PM
Silo Pharma’s QwikAgents Joins NVIDIA Developer Program To Enhance And Advance AI Agent Integration PlatformBenzinga · Jul 7, 2026, 12:20 PM
Silo Pharma Engages Drug-Device Development Partner Resyca To Carry Out Trial To Evaluate Nasal Spray System For Nose-To-Brain Delivery Of SPC-15 To Treat Post-Traumatic Stress DisorderBenzinga · Jun 29, 2026, 8:20 PM
Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.Benzinga · Jun 23, 2026, 12:25 PM